Exploratory analysis of EGFR FISH criteria in Japanese non-small cell lung cancer patients treated with gefitinib

被引：0
|
作者：
Kazuo, K.
Morrison, L. E.
Kimura, H.
Sone, T.
Araya, T.
Tamori, S.
Tanbo, Y.
Fujimura, M.
Speake, G.
Holloway, B. R.
机构：
[1] Kanazawa Univ, Kanazawa, Ishikawa, Japan
[2] Abbott Mol Inc, Des Plaines, IL USA
[3] AstraZeneca, Macclesfield, Cheshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7599
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib.
    Varella-Garcia, M.
    Mitsudomi, T.
    Yatabe, Y.
    Kosaka, T.
    Nakajima, E.
    Franklin, W.
    Bunn, P. A., Jr.
    Hirsch, F. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 405S - 405S
  • [2] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [3] Inherited EGFR variants and survival in patients with non-small cell lung cancer (NSCLC) treated with gefitinib.
    Gregorc, V
    Hidalgo, M
    Spreafico, A
    Aondio, G
    Cusatis, G
    Marsh, S
    Steinberg, SM
    Ludovini, V
    Villa, E
    Sparreboom, A
    Baker, SD
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9079S - 9079S
  • [4] Plasma EGFR and Her2 levels in non-small cell lung cancer patients treated with gefitinib
    Kasahara, K.
    Tamori, S.
    Sakai, A.
    Tambo, Y.
    Araya, T.
    Sone, T.
    Kimura, H.
    Fujimura, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer
    Hosokawa, Shinobu
    Toyooka, Shinichi
    Fujiwara, Yoshiro
    Tokumo, Masaki
    Soh, Junichi
    Takigawa, Nagio
    Hotta, Katsuyuki
    Yoshino, Tadashi
    Date, Hiroshi
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    LUNG CANCER, 2009, 66 (01) : 107 - 113
  • [6] CLINICAL EXPERIENCE USE GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH A MUTATION EGFR
    Vozniy, Eduard
    Popov, Anatoly
    Galkin, Michail
    Astrakhankina, Tamara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1214 - S1214
  • [7] Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer
    Chen, Jing
    Gu, Runxia
    Wang, Qiong
    Dassarath, Meera
    Yin, Zhongyuan
    Yang, Kunyu
    Wu, Gang
    ONKOLOGIE, 2012, 35 (09): : 509 - 513
  • [8] Comparison of EGFR FISH and EGFR SISH in non-small cell lung cancer
    Wulf, M.
    Behnke, S.
    Soltermann, A.
    Tischler, V
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 : 153 - 153
  • [9] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [10] Association of the EGFR gene polymorphisms with clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib
    Ma, F.
    Lin, D.
    Sun, T.
    Chu, D.
    Zhang, X.
    Wang, Z.
    Wang, J.
    Shi, Y.
    Sun, Y.
    Xu, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345